New hope for Hard-to-Treat nasopharyngeal cancer: targeted drug HLX43 enters phase 2 trial

NCT ID NCT06839066

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests HLX43, a drug that targets a protein called PD-L1 on cancer cells and delivers a toxin to kill them. It is for people with recurrent or metastatic nasopharyngeal carcinoma who have failed or cannot tolerate second-line therapy. About 70 participants will receive one of three doses to find the best balance of safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX43 (an antibody-drug conjugate that targets PD-L1 and delivers a chemotherapy-like toxin to cancer cells)
What this could lead to: If successful, this could offer a new treatment option for people with advanced nasopharyngeal cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase trial (70 people) testing different doses, so it may not show strong enough benefit or could have unexpected side effects. The drug is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen
RECRUITING

Shenzhen, Guangdong, China
Dongguan People's Hospital
RECRUITING

Dongguan, Guangdong, China
First Affiliated Hospital of Gannan Medical University
RECRUITING

Ganzhou, Jiangxi, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Guangxi Medical University Cancer Hospital
RECRUITING

Nanning, Guangxi, China
Guizhou Medical University Cancer Hospital
RECRUITING

Guiyang, Guizhou, China
Sichuan Cancer Hospital
RECRUITING

Chengdu, Sichuan, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
RECRUITING

Guangzhou, Guangdong, China
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China
Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China
Zhongshan City People's Hospital
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.